Management of Hepatitis C Infection
Summary
- Sofosbuvir/velpatasvir/voxilaprevir is approved for 12-week use in patients with compensated cirrhosis who either have genotype 1-6 HCV infection and were previously treated with an NS5A inhibitor–containing regimen or have genotype 1a or 3 HCV infection and were previously treated with sofosbuvir[FDA Sofosbuvir Velpatasvir Voxilaprevir]
- High SVR12 rates observed in phase III trials in patients with compensated cirrhosis and previous DAA experience
- POLARIS-1: SVR12 93% in patients with cirrhosis, genotype 1-6 HCV infection, and previous NS5A inhibitor experience[Bourlière 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment